Aureus Asset Management LLC Raises Position in Eli Lilly and Company $LLY

Aureus Asset Management LLC lifted its stake in Eli Lilly and Company (NYSE:LLY) by 15.6% in the first quarter, Holdings Channel.com reports. The firm owned 4,008 shares of the company’s stock after buying an additional 542 shares during the period. Aureus Asset Management LLC’s holdings in Eli Lilly and Company were worth $3,686,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Norges Bank bought a new position in Eli Lilly and Company during the fourth quarter valued at $12,976,634,000. J. Stern & Co. LLP lifted its holdings in shares of Eli Lilly and Company by 46,191.3% in the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock worth $4,047,245,000 after acquiring an additional 4,038,502 shares during the last quarter. Cardano Risk Management B.V. boosted its stake in shares of Eli Lilly and Company by 876.1% during the 4th quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock worth $2,552,419,000 after purchasing an additional 2,131,734 shares during the period. Fifth Third Bancorp grew its holdings in Eli Lilly and Company by 321.3% during the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock valued at $1,805,959,000 after purchasing an additional 1,497,423 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in Eli Lilly and Company by 10.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock worth $16,024,022,000 after purchasing an additional 1,432,069 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Neutral Sentiment: Eli Lilly confirmed it will report second-quarter 2026 results on August 5, with a conference call the same day, keeping attention on the company’s upcoming earnings update. Lilly confirms date and conference call for second-quarter 2026 financial results announcement
• Neutral Sentiment: An update on Lilly’s EMPRISE diabetes study added some interest in the company’s clinical data pipeline, but the market’s focus is still centered on the legal battle with Novo Nordisk. Real-World Diabetes Data: What Eli Lilly’s EMPRISE Update Means for LLY Investors
• Positive Sentiment: Broader pharma stocks got a lift after reports that generic drugs imported into the U.S. will remain under a zero-percent tariff for two more years, which could support sentiment across the sector, including Lilly. These major drug stocks rally after Trump’s zero tariff announcement

Wall Street Analyst Weigh In

Several research analysts have issued reports on LLY shares. Truist Financial boosted their target price on Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. The Goldman Sachs Group reiterated a “buy” rating and issued a $1,283.00 price target on shares of Eli Lilly and Company in a report on Friday, May 22nd. Rothschild & Co Redburn raised their price target on Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. Royal Bank Of Canada boosted their price objective on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a report on Wednesday, July 8th. Finally, JPMorgan Chase & Co. upped their price objective on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a research report on Tuesday, July 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,283.64.

Eli Lilly and Company Trading Down 1.0%

Shares of NYSE LLY opened at $1,163.70 on Thursday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,249.45. The firm has a market cap of $1.10 trillion, a PE ratio of 41.34, a price-to-earnings-growth ratio of 1.49 and a beta of 0.51. The business has a fifty day simple moving average of $1,129.17 and a two-hundred day simple moving average of $1,038.31. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business’s revenue was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts expect that Eli Lilly and Company will post 34.21 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.